Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001209191-17-008201
Filing Date
2017-02-07
Accepted
2017-02-07 06:49:32
Documents
1
Period of Report
2017-02-03

Document Format Files

Seq Description Document Type Size
1 FORM 4 SUBMISSION doc4.html 4  
1 FORM 4 SUBMISSION doc4.xml 4 6564
  Complete submission text file 0001209191-17-008201.txt   7933
Mailing Address 3344 N. TORREY PINES CT. SUITE 200 LA JOLLA CA 92037
Business Address 3344 N. TORREY PINES CT. SUITE 200 LA JOLLA CA 92037 (858) 875-8600
Orexigen Therapeutics, Inc. (Issuer) CIK: 0001382911 (see all company filings)

EIN.: 651178822 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations

Mailing Address 3344 N. TORREY PINES COURT LA JOLLA CA 92037
Business Address
Lynch Thomas P. (Reporting) CIK: 0001659824 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-33415 | Film No.: 17577180